Kamada (KMDA) AI Stock Analysis

444 Followers

Kamada

(NASDAQ:KMDA)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Raised growth outlookRaised guidance indicates management sees durable demand and operating momentum rather than a one-quarter improvement. The projected revenue and EBITDA growth should strengthen internal funding capacity, support investment in the portfolio, and improve earnings visibility over the next several quarters.

Negative Factors

Gross-margin pressureThe year-over-year gross-margin decline suggests that recent revenue growth has not translated fully into stronger unit economics. If the pressure persists, it could limit EBITDA expansion, reduce the benefit of commercial growth, and constrain the cash available for reinvestment.

Kamada (KMDA) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $1.47B
Dividend Yield: 5.17%
Average Volume (3M): 134.47K
Price to Earnings (P/E): 18.8
Beta (1Y): 0.60
Revenue Growth: 12.64%
EPS Growth: 21.73%
Country: US
Employees: 462
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - Specialty & Generic

Kamada Business Overview & Revenue Model

Company Description

Kamada Ltd. is a biopharmaceutical firm specializing in protein therapies derived from blood plasma. Its operations are divided into two primary areas: developing and marketing its own proprietary products, and distributing a portfolio of third-party...

Kamada Earnings Call Summary

Earnings Call Date:Nov 09, 2026(Q3-2026)|% Change Since:12.45%|Next Earnings Date:Mar 17, 2027

Earnings Call SentimentPositive

The call was strongly positive, characterized by record nine-month revenue, double-digit growth in revenue and profitability, raised 2026 guidance, expectations for continued double-digit growth in 2027, expanding demand across the commercial portfolio, new biosimilar launches, and a significant plasma supply agreement. The principal negatives were the nine-month gross-margin decline, higher operating expenses supporting expanded operations, cash and short-term investments being slightly below year-end 2025, plasma operations not yet contributing to reported results, and the absence of a completed M&A transaction. Highlights significantly outweighed lowlights.

Positive Updates

Record Nine-Month Revenue and Strong Profitability Growth

Nine-month 2026 revenue reached a record $152.2 million, up approximately 12% year-over-year. Adjusted EBITDA was $40.9 million, up 20% year-over-year with a 27% margin, while net income was $21.4 million, up 29% year-over-year.

Negative Updates

Nine-Month Gross Margin Declined Year-over-Year

For the first nine months of 2026, gross profit was $64.9 million and gross margin was 43%, compared with $59.4 million and a 44% gross margin in the first nine months of 2025.

Company Guidance

Kamada increased 2026 annual guidance to a range of $205 million to $208 million in revenues and $52 million to $54 million of adjusted EBITDA, with the midpoints representing 14% and 26% growth, respectively, compared to 2025 results; it projects continued double-digit profitable growth during 2027, with detailed financial guidance for 2027 provided in January. The biosimilar portfolio is expected to generate approximately $10 million in annual revenues in 2028, growing to approximately $20 million to $25 million in annual revenues by 2030, with at least 2 additional biosimilar products expected to launch next year; initial commercial sales under the 3-year sales agreement of approximately $50 million are included in current annual guidance.

Kamada Risk Analysis

Kamada disclosed 99 risk factors in its most recent earnings report. Kamada reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks

1.Our current working capital may not be sufficient to support our growth strategy, including any future M&A or similar transactions.Q4, 2025

2.From time to time, we participate in Investigator-Initiated Clinical Trials, which are conducted and managed independently by external investigators or academic institutions. Any failure by investigators or institutions to properly conduct these trials could restrict our ability to fully leverage clinical insights gained from such studies and impede our product commercialization effortsQ4, 2025

3.Our manufacturing operations require significant ongoing capital investments, upgrades and large-scale projects, which may require us to incur debt or issue additional equity and may not deliver expected returns.Q4, 2025

Kamada Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

KMDA against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IL:TEVA	66Neutral	ILS 157.40B	94.22	―	―	-10.56%	-29.51%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
IL:INCR	39Underperform	ILS 147.50M	-3.27	-8.77%	―	―	―

* General Sector Average

Performance Comparison

KMDA and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
KMDA	Kamada Ltd	8.13	1.40	20.77%
IL:INCR	Intercure	1247.00	-1024.00	-45.09%
IL:TEVA	Teva Pharmaceutical Industries Limited	13540.00	5102.00	60.46%
IL:SEMG	Seach Medical Group Ltd.	270.10	20.76	8.32%
IL:PSRX	Psyrx Bio-Tech	61.90	-79.20	-56.13%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Kamada AI Stock Analysis